Traduction de «health » (Néerlandais → Français) :

TERMINOLOGIE

periodiek onderzoek (jaarlijks)(lichamelijk) | 'health check-up' NNO
Bilan de santé SAI Examen périodique (annuel) (physique)

TRADUCTIONS EN CONTEXTE

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council
BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

“Comparative cost analysis: Community based services as an alternative to institutions" , tender no. VT/2005/021, Official Journal on 22 June 2005 N° 2005/S 119-117014 [http ...]
K. ; Paul R (Hrsg.) : Health Promoting Hospitals in Practice: Developing Projects and Networks – Conrad, Gamburg Inclusion Europe, Included in Society (2003-2004), projet réalisé dans le contexte du Fonds social européen ( [http ...]

BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI
BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI

Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products
Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products

and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS
and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS

Alleen belangrijke basiswetgeving is hier vermeld. Voor de overige wetgeving met betrekking tot farmaceutische producten, zie: voor geneesmiddelen voor menselijk gebruik: [http ...]
Produits à usage humain: [http ...]

World Association of Infant Mental Health 14th Congress (WAIMH 2014) (Edinburgh, UK - United Kingdom, 02-05 juli 2015) kenes-group.com
World Association of Infant Mental Health 14th Congress (WAIMH 2014) (Edinburgh, UK - United Kingdom, 02-05 Juillet 2015) kenes-group.com

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.